Notice of Special Interest (NOSI): Administrative Supplements for Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) Phase I Projects to Address Vaccine Hesitancy and Uptake
Notice Number:

Key Dates

Release Date:

April 13, 2021

First Available Due Date:
May 10, 2021
Expiration Date:
May 11, 2021

Related Announcements

RFA-OD-22-011 - Emergency Award: Rapid Acceleration of Diagnostics Tribal Data Repository (RADx TDR) (U24 Clinical Trial Not Allowed).

NOT-OD-21-125  – Notice of Correction to NOT-OD-21-103

NOT-OD-21-103  – Notice of Special Interest (NOSI): Emergency Competitive Revisions for NIH Grants to Add or Expand Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations – RADxSM-UP Phase II (Emergency Supplement - Clinical Trial Optional)

PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

RFA-OD-21-008 - Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations – RADx-UP Phase II (U01 Clinical Trial Optional)

RFA-OD-21-009 Emergency Award: RADxSM-UP -Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01, Clinical Trial Optional)

NOT-OD-21-097- Notice of Intent to Publish a Research Opportunity Announcement for RADxSM-UP Return to School Diagnostic Testing Approaches (OT2 Clinical Trial Optional)

NOT-OD-21-065- Notice of Intent to Publish a Research Opportunity Announcement for RADx-UP Return to School Diagnostic Testing Approaches (OT2 Clinical Trial Optional)

NOT-OD-21-072- Notice of Correction to NOT-OD-21-065 "Notice of Intent to Publish a Research Opportunity Announcement for RADx-UP Return to School Diagnostic Testing Approaches (OT2 Clinical Trial Required)" for Clinical Trial Requirements

NOT-HL-20-806- NHLBI confirms participation in NOT-OD-20-119, NOT-OD-20-120, and NOT-OD-20-121 (Research on COVID-19 Testing among Underserved and/or Vulnerable Populations)

NOT-OD-20-131- Notice of Pre-Application Webinar for the RADx-UP Initiative

PA-20-135- Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)

NOT-OD-20-121- Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

NOT-OD-20-120- Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

NOT-OD-20-119- Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

RFA-OD-20-013- Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)

NOT-OD-20-138- Notice of Correction to NOT-OD-20-119, NOT-OD-20-120, NOT-OD-20-121 Eligibility Section

NOT-HL-20-803- Notice of NHLBI Participation in NOT-OD-20-119

NOT-HL-20-804-Notice of NHLBI Participation in NOT-OD-20-120

NOT-HL-20-805- Notice of NHLBI Participation in NOT-OD-20-121
NOT-OD-20-157- Notice to Clarify and Correct Eligibility in Notices of Special Interest under the Rapid Acceleration of Diagnostics Underserved Populations (RADx-UP) Program

NOT-OD-21-038- Updated Instructions on Interim Reporting and Carryover for RADx-UP Recipients

Issued by

Office of The Director, National Institutes of Health (OD)

National Heart, Lung, and Blood Institute (NHLBI)

National Institute on Aging (NIA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Allergy and Infectious Diseases (NIAID)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Drug Abuse (NIDA)

National Institute of Environmental Health Sciences (NIEHS)

National Institute of General Medical Sciences (NIGMS)

National Institute of Mental Health (NIMH)

National Institute of Nursing Research (NINR)

National Institute on Minority Health and Health Disparities (NIMHD)

National Library of Medicine (NLM)

National Center for Complementary and Integrative Health (NCCIH)

National Center for Advancing Translational Sciences (NCATS)

National Cancer Institute (NCI)

Office of The Director, National Institutes of Health (OD)


This Notice of Special Interest (NOSI) seeks to support administrative supplements to Rapid Acceleration of Diagnostics-Underserved Populations (RADxSM-UP) recipients to address the urgent need to expand outreach and education efforts to promote testing and foster vaccine confidence, acceptance, and uptake in underserved and vulnerable communities. These 1-year projects will develop, implement, and evaluate brief interventions at RADxSM-UP testing sites to maximize effective outreach, education, communication, and facilitate the dissemination and uptake of testing and vaccines in underserved and vulnerable communities. The funding for this supplement program is provided from the American Rescue Plan Act of 2021.

Applications are being requested from current RADx-UP recipients from the following Funding Opportunity Announcements and Notices of Special Interest:

NOT-OD-20-121- Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

NOT-OD-20-120- Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

NOT-OD-20-119- Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations

Key Definitions

This NOSI is applicable to underserved and vulnerable populations that are COVID-19 vulnerable due to medical, geographic, and social factors, as defined below (referred to as “underserved and vulnerable” elsewhere in this NOSI):

Underserved: NIH-designated health disparity populations and other groups known to experience barriers to accessing needed health care services or have inadequate health care coverage. A full description can be found at

COVID-19 medically and/or socially vulnerable populations: Homeless populations; individuals involved with the criminal or juvenile justice systems (incarcerated or under community supervision); pregnant and post-partum women; children and adolescents; individuals living in congregate housing such as shelters or residential treatment facilities; individuals in overcrowded housing; individuals with substance use disorders or serious mental illness; migrant and immigrant populations; residents of tribal lands or reservations; communities exposed to high rates of air pollution or other toxic exposures; communities with high levels of social vulnerability; residents of nursing homes and assisted living facilities; community-dwelling older adults; individuals with intellectual, developmental, sensory, or physical disabilities, cognitive impairment or dementia, or communication disorders; individuals with medical comorbidities known to increase risk of severe COVID-19, including heart failure and related cardiovascular conditions, diabetes mellitus, chronic lung disease, obesity, HIV/AIDS; and rural and remote communities.

Background and Goals

SARS-CoV-2 is the causative agent of COVID-19, a respiratory disease that exhibits a wide range of clinical outcomes from asymptomatic and mild disease to severe complications. United States Food and Drug Administration (FDA)-authorized/approved COVID-19 diagnostic testing and vaccine uptake are two essential tools for slowing the spread of the virus and preventing future outbreaks. NIH is committed to applying scientific methods to ensure that all populations have optimal access to and uptake of COVID-19 public health prevention and mitigation interventions, including SARS-CoV-2 testing and vaccines, as well as behavioral strategies (e.g., handwashing and sanitizing, wearing well-fit masks, avoiding indoor gatherings and physical distancing). NIH also seeks to combat widespread misinformation about COVID-19 through bidirectional and community responsive engagement, communication, and the dissemination of educational and other resources among underserved and vulnerable communities.

The overarching goal of the RADxSM-UP initiative is to understand and address factors associated with COVID-19 morbidity and mortality disparities among underserved and vulnerable populations. The RADxSM-UP consortium consists of 53 community-engaged research projects focused on building the evidence base of approaches to increase access to and uptake of COVID-19 diagnostics, and 16 projects are seeking tounderstand the social, ethical, and behavioral implications (SEBI) of testing. Collectively, RADxSM-UP projects aim to strengthen the available data on disparities in infection rates, disease progression and outcomes, and on differences in testing access and uptake patterns, and identifying strategies to address disparities in COVID-19 diagnostics (and related repeat testing, contact tracing, and referrals).

Even with the availability of SARS-CoV-2 vaccines, testing will remain an important component of the public health response to the COVID-19 pandemic. Testing will also remain vital for individuals who will not accept vaccination due to concerns about safety, vaccine hesitancy, or other uncertainties. With the potential for SARS-CoV-2 reinfection, new viral variants arising that may be resistant to current vaccines, and possible transmission of SARS-CoV-2 from vaccinated to unvaccinated people, testing will remain a major component of the long-term strategy to control the spread of the virus.

To facilitate uptake of vaccines and testing, a number of current challenges require continued attention. Distrust of government-supported science and the health care system, vaccine hesitancy, and health misinformation have hampered the U.S. public health system’s response to the pandemic. To support a coordinated national strategy for implementing vaccinations and testing, we must apply evidence-informed outreach and communication strategies to foster trust, develop tailored and targeted communication efforts, address misinformation about vaccines and testing, and increase efforts to foster vaccine and testing confidence and uptake necessary to protect all Americans. Current national surveys point to lower willingness to accept a vaccine in some populations; more detailed and disaggregated data are needed to understand how to foster vaccine confidence to increase access to vaccines and testing across all underserved and vulnerable populations that are the foci of RADxSM-UP.

Understanding and addressing vaccine hesitancy and uptake is among the goals of a related NIH-wide initiative, the Community Engagement Research Alliance (CEAL) Against COVID-19 Disparities. The mission of CEAL is to provide trustworthy information through active community engagement and outreach to the people hardest-hit by the COVID-19 pandemic, including African Americans, Hispanics/Latinos, and American Indians/Alaska Natives, with the goal of building long-lasting partnerships as well as improving diversity and inclusion in our research response to the COVID-19 pandemic. CEAL has been developing evidence-informed communication resources to address COVID-19 misinformation, engage trusted partners and messengers in delivering accurate information, and to facilitate inclusion of racial/ethnic populations in COVID-19 clinical trials.

This NOSI will provide an opportunity for RADxSM-UP Phase I investigators to integrate vaccine hesitancy and uptake into their funded projects, which are designed to answer COVID-19 testing-related questions. The 1-year projects in response to this supplemental NOSI may develop, test, and evaluate brief interventions at RADxSM-UP testing sites with the goals of maximizing effective outreach and education, and facilitating the dissemination and uptake of testing and vaccines in underserved and vulnerable communities. RADxSM-UP Phase I projects will apply the program’s experience in community-engaged research, communication and behavioral science expertise, existing infrastructures, and extant findings from testing studies to address emerging testing and vaccination-related challenges. Applicants are strongly encouraged to form strategic collaborations with CEAL research teams working in the same geographic areas and/or with the same populations, leveraging the other’s existing resources to build a robust network aimed at increasing engagement with underserved communities to promote public health measures, clinical trial enrollment, testing for SARS-CoV-2, vaccination, and other mitigation measures, as well as to better understand the factors that prevent access and adoption of such actions. Proposals may also apply intersectional approaches to this work (e.g., underserved healthcare workers exhibiting significant vaccine hesitancy).

Projects will integrate targeted and tailored communication and educational interventions developed by CEAL, or other credible information sources (e.g., Centers for Disease Control and Prevention), to address vaccine hesitancy, distrust, and acceptance into RADxSM-UP diagnostic testing project sites. These collaborative projects will be part of the RADxSM-UP consortium and serve as a resource for COVID-19 diagnostic testing and expand the reach of CEAL’s communication and outreach campaigns.

Projects will address key questions, including but not limited to:

  • What brief intervention approaches can sustainably improve the uptake of COVID-19 prevention tools, including testing, vaccines, and behavioral mitigation strategies?
  • How can RADxSM-UP community partnerships be leveraged to foster COVID-19 vaccine confidence and uptake?
  • How can CEAL-developed, evidence-informed resources be implemented within the contexts of RADxSM-UP testing and SEBI projects?
  • How can evidence-informed resources be adapted and scaled for dissemination and implementation within the context of RADxSM-UP?
  • How can community-placed clinical centers and other front-line clinics be leveraged to provide an opportunity for a “warm hand-off” to vaccination at the point of testing?
  • How can the “teachable moment” concept be applied to encourage COVID-19 vaccination at the point of testing?
  • What are the health and public health systems-change interventions to promote patient engagement, access, acceptability, and decision-making from testing to vaccination?
  • How can increased communication and education efforts improve the uptake of prevention measures including testing and vaccine uptake?
  • What are the optimal education and communication strategies to mitigate the impact of misinformation and address vaccine hesitancy in particular communities?

Research Topics

Scientific areas of interest for research supported by this NOSI among underserved and vulnerable populations include, but are not limited to:

  • Brief interventions to improve awareness and uptake of COVID-19 prevention tools, including testing, vaccines, and behavioral mitigation strategies
  • Strategies to communicate culturally and linguistically appropriate information about COVID-19 vaccines to foster vaccine confidence and increase acceptance at the point of COVID-19 testing
  • Effective strategies to adapt CEAL-developed resources into RADxSM-UP testing and SEBI projects
  • Interventions implemented in community-based clinics (e.g., FQHCs) and other front-line clinical sites (e.g., pharmacies, urgent care clinics) to provide an opportunity for a “warm hand-off” from testing to vaccination
  • Brief interventions to apply the “teachable moment” concept to address COVID-19 vaccine hesitancy at the point of testing
  • Dissemination of targeted or tailored education and messaging strategies to mitigate the impact of COVID-19 misinformation and/or to address vaccine hesitancy
  • Dissemination and communication strategies to amplify or extend the reach of the voices of local community leaders/stakeholders and health professionals to promote COVID-19 prevention tools (e.g., testing, vaccination, and behavioral strategies)
  • High reach, low intensity interventions to iteratively evaluate messages to increase the uptake of COVID-19 testing and vaccination
  • Practical health and community systems-level interventions to address emerging barriers to COVID-19 testing and vaccine access
  • Interventions to promote adherence to timely completion of 2-dose SARS-Co-V-2 vaccine regimens, when applicable, and examining factors that predict non-adherence
  • Interventions to provide evidence-informed information on potential side-effects and expectations, including those related to asymptomatic testing, post-vaccination
  • Interventions to proactively address and ameliorate the adverse impacts of exposure to vaccine-related misinformation
  • Efforts to evaluate the impact of local contextual messages, media landscape, and messaging forums (e.g., community townhall meetings) on testing, and vaccination, and other mitigation strategies
  • Efforts to communicate and facilitate patient and clinician decision-making and communication of post-vaccination COVID-19 mitigation behaviors and testing recommendations

The proposed RADxSM-UP and CEAL projects must demonstrate relevance of the scientific questions to COVID-19 among underserved and vulnerable populations. Projects should focus on developing and disseminating outreach, communication, and education programs based on available guidance (e.g., from CEAL and The COVID-19 Vaccination Communication through rigorous research designs (e.g., randomized controlled trials, stepped wedge designs, multiphase optimization strategy (MOST) designs, pragmatic clinical trials, interrupted time series, dynamic wait list design, hybrid designs, sequential multiple assignment trial (SMART) designs, and adaptive designs). Quasi-experimental designs and mixed methods studies are also acceptable, particularly for some vulnerable populations where randomization may not be possible due to small population sizes or other factors. Projects must describe research strategies that will reflect the evolving landscape and increased availability of COVID-19 testing and vaccines. Projects must also demonstrate the ability to recruit and retain an adequate number of participants within the specified target populations and include sample size and power calculations. Additional information is available at

Where possible, applications should work towards practical outcomes or products towards improving acceptability and access of COVID-19 diagnostics and vaccines. Researchers should address the outcomes deemed as “high priority” by members of the community where interventions take place. These studies will focus on specific communities, yet they should also consider the extent to which findings can be generalized or adapted and implemented across other underserved and vulnerable populations. Applications should briefly describe the potential, where possible, of study approaches and findings for broader scale-up and population health impact and include plans for the development of materials or toolkits to facilitate adaptation, dissemination, and potential for implementation and scale up in other populations or settings.

For projects incorporating testing, testing capacity should include access to FDA-authorized or approved test kits and related supplies (including point-of-care testing), and Clinical Laboratory Improvement Amendments (CLIA) certified laboratories (e.g., hospital, public health, or commercial) to administer the tests and return test results as quickly as possible. The proposed (and implemented) COVID-19 testing must be fully FDA authorized or approved. This includes sample collection, assays, and test performance. Strategies to maximize return of test results, plans for follow up, and familial and caregiver testing (when indicated) should consider literacy, health literacy, numeracy, cultural preferences, and language barriers.

Additional Requirements

NIH is striving for consistency and high levels of rigor and reproducibility in all research, particularly in programs related to the COVID-19 pandemic. All researchers engaging human participants in their projects are required to use a set of Common Data Elements (CDEs) to standardize the collection of data and ensure that data can be aggregated and compared across study populations and research topics (where not otherwise prohibited, such as by Tribal authority).This data standardization will permit evaluation of the overall RADxSM-UP consortium and impacts on COVID-19 disparities in specific populations, facilitate analysis of research questions and may inform policy at the local, community, and/or Tribal levels. Projects responding to this funding opportunity are required to collect the NIH RADxSM-UP Tier 1 Common Data Elements. Permission from participants to collect and share these CDEs will be given through specific language in the Informed Consent Form (ICF). Please refer to the public Link for CDCC reference Material and resources for testing: and the public link for CDCC reference materials for new project grant applications: Common Data Elements, Informed Consent Language, Data Use Agreement recommended language: to ensure alignment with data collection requirements.

Recipients will work closely with the CDCC on data sharing activities as part of the RADxSM-UP consortium to advance the science of health disparities research in COVID-19 testing across the country. As an initiative that prioritizes community engagement, awardees will work with the CDCC to identify the scope of data sharing agreements that are acceptable to community partners, allow recruitment and retention of participants, and build trust, while contributing to consortium activities. The scope of data sharing may include the following: 1)depositing de-identified data in the CDCC and NIH RADx Data Hub, 2) sharing de-identified data with the CDCC and NIH for possible future scientific research, 3) sharing identifiable data topermit re-contact of participants for future follow-up and participation in future research; and/or 4) sharing identifiable data to perform linkages with clinical and population data sets, to understand health outcomes of the COVID-19 pandemic among underserved and vulnerable populations. Applicants are encouraged to discuss acceptability of one or more of these options for data sharing prior to application.

Any data collected as part of this funding announcement will be archived as de-identified data in the NIH RADx Data Hub and will enable authorized community members, health researchers, and scientists in the Federal government to understand the impact of the COVID-19 pandemic on the well-being, risk, resilience and disparities in underserved and vulnerable communities across the U.S. and the U.S. Territories. Funded projects will share study data collection instruments and other research products with other RADxSM-UP funded projects through the CDCC.

Projects funded through this NOSI are strongly encouraged to use the following resources for the assessment of other constructs:

  • Data Harmonization for Social Determinants of Health via the PhenX Toolkit: Investigators involved in human-subject studies are strongly encouraged to employ a common set of tools and resources that will promote the collection of comparable data on social determinants of health (SDOH) across studies. In particular, studies with human participants should incorporate SDOH measures from the Core and Specialty collections that are available in the Social Determinants of Health Collection of the PhenX Toolkit (
  • Existing COVID-19 survey items and investigator contact information are publicly available through two NIH-supported platforms: the NIH Public Health Emergency and Disaster Research Response (DR2) and the PhenX Toolkit Researchers addressing COVID-19 questions, whether population-based or for clinical research, are strongly encouraged to consider these COVID-19 specific survey item repositories and select existing survey items or protocol modules currently being fielded.

Additionally, researchers with funding through this NOSI are strongly encouraged to share their survey items to make them public for other researchers to consider by submitting their surveys to

Applications nonresponsive to terms of this NOSI will not be considered. The following types of projects would generally not be appropriate and may be deemed non-responsive:

  • Projects without a focus on one or more underserved and COVID-19 vulnerable populations
  • Projects that do not demonstrate an equitable relationship or engagement strategy with the underserved and vulnerable populations of interest
  • Projects that do not include community engagement efforts
  • Projects that involve new foreign components; additional funding for existing foreign components; or COVID-19 testing or SEBI outside of the United States, its territories and possessions, the Commonwealth of Puerto Rico, or the Trust Territory of the Pacific Islands
  • Projects that are exclusively qualitative (though mixed quantitative and qualitative are acceptable)
  • Projects that do not have an infrastructure to rapidly report study findings and impact to the CDCC
  • Projects that are conducting testing, but do not include FDA-authorized or approved testing strategies, materials, data collection, assay strategies, or do not present a plan to return results to participants
  • Projects that are not within the scope of the parent award, and a logical extension of the original aim.

Review Process

Applications will be evaluated for scientific and technical merit by an appropriate internal NIH staff review panel, in accordance with the review criteria specified in PA-20-272.

Funds available

  • Individual requests can be no more than $300,000 in total costs per year for up to one year. Funds are available for up to 15 awards.


  • OD plans to make awards using funds provided in the emergency supplemental appropriations for COVID-19 and coronavirus research: “ American Rescue Plan Act of 2021, PL 117-2”. Funds awarded using appropriations provided by the "American Rescue Plan Act of 2021, PL 117-2"” will be issued in unique subaccounts in the HHS Payment Management System and will require separate financial reporting from any other funds awarded
  • In addition to the annual RPPR, recipients are required to submit an interim progress report every six months outlining key milestones that have been met.
  • Recipients must upload the interim report using the Additional Materials (AM) tool in eRA. The Authorized Organization Official is required to submit interim reports to the Grants Management Official named on the Notice of Award using AM.
  • The interim progress report must outline for each award the following:
    • For each specific aim, a brief summary of major activities, significant results, and key outcomes or other achievements.

Application and Submission Information

Applications in response to this NOSI must be submitted using one of the following target opportunities or subsequent reissued equivalent.

  • PA-20-272- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) is intended to provide funds for NIH recipientswhere the work proposed in the supplements is within the scope of the ongoing grant
  • The funding instrument, or activity code, will be the same as the parent award.
  • Only one (1) application per RADxSM-UP Phase I grant will be considered.
  • Applicants should describe their ideas for working with other RADxSM-UP and CEAL sites to accomplish project goals, and their willingness to adhere to policies and procedures determined in cooperation with the CDCC.
  • Projects must focus on and include one or more underserved and vulnerable populations (identified above). Applicants should demonstrate a successful record of collaboration with existing community partners.
  • NIH reminds applicants that the appropriate consideration of sex and gender as described in NOT-OD-15-102 is NIH policy and a consideration for NIH support.

All instructions in the SF424 (R&R) Application Guide and in the target funding opportunity announcement (PA-20-272) must be followed, with the following additions

The Research Strategy section of the application is limited to 6 pages.

  • The project period will be limited to one year and must reflect the needs of the project.
  • The parent award must be on-going when the supplement application is submitted , regardless of the time remaining on the current project. Grants currently in a no-cost extension are eligible to apply.
  • Applicants should address whether ongoing or potential future public health restrictions (e.g., closures, physical distancing) might affect the research approach and, if so, include a plan to prevent or mitigate any effect on the proposed study.
  • Applications will be accepted on a rolling basis through May 10 2021 by 5:00 PM local time of the applicant organization. This NOSI expires on May 11, 2021. An application submitted in response to this NOSI that is received on May 11, 2021 or later will be withdrawn.
  • The process for Streamlined Submissions using the eRA Commons cannot be used for PA-20-272.
  • IMPORTANT: For funding consideration, all applicants must designate NOT-OD-21-101 in the Agency Routing Identifier field (Box 4b) of the SF424 (R&R) Form. Applications without this information in Box 4b will not be considered for this initiative.
  • All applications (including those for multi-project activity codes) must be submitted electronically using a single-project application form package
    • Administrative supplement applications to PA-20-272 must use the application form package with the Competition ID that contains “FORMS-F-ADMINSUPP”.

Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact and discuss their proposed research/aims with Program staff listed on this NOSI well in advance of the application receipt date to better determine appropriateness and interest of the relevant Institute.

Applications nonresponsive to the terms of this NOSI will not be considered for this NOSI.


Please direct all inquiries to:

Scientific/Research Contact(s)

Please contact the Program Officer for the Parent Award.

Peer Review Contact(s)

Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).

Financial/Grants Management Contact(s)

Please contact the Grants Management Contact(s) for the Parent Award.

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices